A new study identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation. The results, published in Cell Medicine Reports on Feb.
Less Invasive Early Lung Cancer Study Receives Top 10 Clinical Research Achievement Award
February 22, 2024
A Weill Cornell Medicine-led research team has been awarded a 2024 Top 10 Clinical Research Achievement Award from the Clinical Research Forum in recognition of an influential 2023 New England Journal of Medicine study on early-stage lung cancer resection.
February 2024 EIPM Director's Memo
February 5, 2024
Dear Members of the Englander Institute,
Thank you all for a very productive January!
Who’s Afraid of Early Cancer Detection?
February 4, 2024
A diagnosis of pancreatic cancer usually means a quick death—but not for Roger Royse, who was in Stage II of the disease when he got the bad news in July 2022. The five-year relative survival rate for late-stage metastatic pancreatic cancer is 3%—which means that patients are 3% as likely to live five years after their diagnosis as other cancer-free individuals.
Task force offers guidance to researchers on use of AI
January 22, 2024
A multidisciplinary task force of Cornell faculty and staff has issued a report offering perspectives and practical guidelines for the use of generative artificial intelligence (GenAI) in the practice and dissemination of Cornell’s academic research.
Immunotherapy and Radiation Combo Shows Improved Outcomes for Non-small Cell Lung Cancer
January 11, 2024
A new study reported that patients with non-small cell lung cancer (NSCLC) treated with a combination of low-dose radiation and immunotherapy had higher progression-free survival compared to patients who received immunotherapy alone two years after treatment. The findings from researchers at Weill Cornell Medicine, NewYork-Presbyterian and Columbia University Vagelos College of Physicians and Surgeons offer hope to those affected by NSCLC, the most common type of lung cancer in the United States—81 percent of all lung cancer diagnoses.
EIPM's 4Q External Newsletter
January 5, 2024
Dear Friend of the Englander Institute for Precision Medicine,
Welcome to our fourth quarterly external newsletter of 2023!
EIPM Researcher Receives Grant for Blood Test to Diagnose Breast Cancer
January 4, 2024
Weill Cornell Medicine researchers received a $2.4 million grant from the U.S. Department of Defense Breast Cancer Research Program to validate a new blood test for the early detection of breast cancer.
Researchers are evaluating Syantra DX Breast Cancer (Syantra Inc.), an experimental diagnostic test that detects specific biomarkers in blood associated with breast cancer. The test uses an artificial intelligence algorithm to determine whether a patient is positive for cancer as soon as detectable by mammogram or possibly earlier, and before symptoms arise.
Dr. Bishoy Faltas Earns Young Investigator Award
December 29, 2023
Dr. Bishoy Faltas, the Gellert Family-John P. Leonard, M.D. Research Scholar and assistant professor of medicine, was awarded the Young Investigator Award by the Society for Basic Urological Research (SBUR). Since its inception, SBUR has committed to education, innovation, advocacy and excellence in basic urology research. The award is given to members under the age of 45 who have made significant contributions to urologic research.